-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Eli Lilly and Company Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$24.54 B | $28.32 B | $28.54 B | $34.12 B | $45.04 B |
| Cost of Revenue |
|
$5.48 B | $7.31 B | $6.63 B | $7.08 B | $8.42 B |
| Gross Profit |
|
$19.06 B | $21.01 B | $21.91 B | $27.04 B | $36.62 B |
| Research & Development |
|
$6.09 B | $6.93 B | $7.19 B | $9.31 B | $10.99 B |
| Selling,General & Administrative |
|
$5.87 B | $6.14 B | $6.44 B | $6.94 B | $8.59 B |
| Operating Expense |
|
$12.21 B | $13.46 B | $13.63 B | $16.25 B | $19.58 B |
| Operating Income |
|
$6.44 B | $7.30 B | $8.65 B | $10.33 B | $17.50 B |
| Net Income |
|
$6.19 B | $5.58 B | $6.24 B | $5.24 B | $10.59 B |
Eli Lilly and Company Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$3.68 B | $3.91 B | $2.21 B | $2.93 B | $3.27 B |
| Inventories |
|
$3.98 B | $3.89 B | $4.31 B | $5.77 B | - |
| Total Current Assets |
|
$17.46 B | $18.45 B | $18.03 B | $25.73 B | $3.52 B |
| Property,Plant and Equipment |
|
$8.68 B | $8.99 B | $10.14 B | $12.91 B | $17.10 B |
| Goodwill |
|
$3.77 B | $3.89 B | $4.07 B | $4.94 B | $5.77 B |
| Total Assets |
|
$46.63 B | $48.81 B | $49.49 B | $64.01 B | $78.71 B |
| Total Liabilities |
|
$40.81 B | $39.65 B | $38.71 B | $53.14 B | $64.44 B |
| Retained Earnings |
|
$7.83 B | $8.96 B | $10.04 B | $10.31 B | - |
| Total Shareholder Equity |
|
$5.64 B | $8.98 B | $10.65 B | $10.77 B | $14.32 B |
| Common Stock |
|
$598.20 M | $596.30 M | $594.10 M | $593.60 M | $592.40 M |
Eli Lilly and Company Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$1.32 B | $1.55 B | $1.52 B | $1.53 B | - |
| Dividends Payout |
|
-$2.69 B | -$3.09 B | -$3.54 B | -$4.07 B | -$4.68 B |
| Capital Expenditures (Capex) |
|
-$2.03 B | -$1.98 B | -$2.99 B | -$7.39 B | -$8.40 B |
| Free Cash Flow (FCF) |
|
$4.47 B | $5.39 B | $4.60 B | -$3.15 B | $414.30 M |
Eli Lilly and Company Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$19.06 B | $21.01 B | $21.91 B | $27.04 B | $36.62 B |
| Gross Profit Margin (%) |
|
77.66% | 74.18% | 76.77% | 79.25% | 81.31% |
| Operating Income |
|
$6.44 B | $7.30 B | $8.65 B | $10.33 B | $17.50 B |
| Operating Income Margin (%) |
|
26.25% | 25.79% | 30.32% | 30.26% | 38.86% |
| Net Income |
|
$6.19 B | $5.58 B | $6.24 B | $5.24 B | $10.59 B |
| Net Income Margin (%) |
|
25.24% | 19.71% | 21.88% | 15.36% | 23.51% |
| EBITDA |
|
$8.91 B | $8.04 B | $8.66 B | $8.57 B | $15.23 B |
| EBITDA Margin (%) |
|
36.32% | 28.40% | 30.34% | 25.11% | 33.81% |
Eli Lilly and Company Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
109.79% | 62.16% | 58.64% | 48.65% | 73.95% |
| Return on Assets (ROA) |
|
13.28% | 11.44% | 12.62% | 8.19% | 13.45% |
| Debt to Equity |
|
294.16% | 188.04% | 152.48% | 234.18% | 234.93% |
| Debt to total asset |
|
35.59% | 34.60% | 32.81% | 39.41% | 42.74% |
| Enterprise value to revenue |
|
6.80 | 9.36 | 12.10 | 16.09 | 16.06 |
| Enterprise value to EBITDA |
|
18.73 | 32.95 | 39.87 | 64.09 | 47.50 |
| Enterprise value |
|
$166.95 B | $264.99 B | $345.27 B | $549.08 B | $723.28 B |
| Cash to Debt |
|
39.17% | 43.00% | 43.63% | 16.81% | 26.21% |
| Tax Rate (%) |
|
14.33% | 9.32% | 8.25% | 20.05% | 16.49% |
| Payout Ratio |
|
43.38% | 55.30% | 56.62% | 77.65% | 44.20% |
